Transcode Therapeutics, Inc.
SEC CIK 1829635 · RNAZ · last insider filing 2025-12-22
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Stover Jack E | Director | filed 2025 - 2025 |
| Czerepak Elizabeth | Director | filed 2025 - 2025 |
| Marquet Magda | Director | filed 2021 - 2024 |
| Calais Philippe | Director | filed 2021 - 2024 |
| Fitzgerald Thomas A | Director · VP, Chief Financial Officer | filed 2021 - 2024 |
| Manting Erik | Director | filed 2021 - 2024 |
| Dudley Robert Michael | Director · Chief Executive Officer | filed 2021 - 2023 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Medarova Zdravka | Chief Technology Officer | filed 2021 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.